{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-012408","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2022-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.022262+00:00","generated_at":"2026-06-23T10:31:17.980444+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"CEL-SCI Phase 3 Multikine at ESMO: 45 responses, all in treatment group (1 in 100B chance), >3x OS benefit","bullets":["45 RECIST neoadjuvant responses including 5 complete; all exclusive to Multikine groups (1 in 100 billion chance).","Overall survival >3x longer for responders vs non-responders.","Early tumor response (pre-surgery) noted only in Multikine groups, not control; prognostic and predictive for OS.","Biomarker analysis: low tumor PDL1, high immune cell density, specific ratios predict Multikine efficacy.","Data from the largest Phase 3 study ever in newly diagnosed locally advanced head and neck cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-012408","json":"https://secwatch.observer/filing/0001654954-22-012408.json","markdown":"https://secwatch.observer/filing/0001654954-22-012408.md","text":"https://secwatch.observer/filing/0001654954-22-012408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/0001654954-22-012408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495422012408/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:31:17.980444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}